Table 2.

JIA core variables at weeks 16 and 60 of adalimumab therapy (as observed)

	Adalimumab with MTX			Adalimumab without MTX
	Mean baseline value	Mean visit value	Mean % change	Mean baseline value	Mean visit value	Mean % change
Week 16
PhGA (mm)	55.8	20.6	−64.8	58.6	10.6	−83.8
PaGA (mm)	44.7	22.1	−50.5	48.6	15.4	−74.5
AJC73	11.0	3.8	−59.9	13.6	3.2	−80.3
LOM69	7.5	3.7	−38.3	5.8	1.6	−76.7
CHAQ	0.7	0.4	−32.8	0.7	0.4	−35.7
CRP (mg/dL)	0.9	0.3	−23.8	3.6	1.7	−65.1
Week 60
PhGA (mm)	55.0	16.7	−74.0	58.6	12.8	−81.5
PaGA (mm)	42.9	16.6	−51.7	48.6	27.0	−48.6
AJC73	11.1	1.9	−81.5	13.6	3.0	−79.8
LOM69	7.6	1.5	−78.7	5.8	2.4	−72.2
CHAQ	0.7	0.2	−46.9	0.7	0.5	−41.0
CRP (mg/dL)	1.0	0.4	−46.6	3.6	1.4	−4.0

AJC active joint count, CHAQ Childhood Health Assessment Questionnaire, CRP C-reactive protein, LOM limitation of motion, MTX methotrexate, PaGA Patient’s Global Assessment, PhGA, Physician’s Global Assessment